Vaccines

A unique 'double feature' in Rocky Mount pairs local artists with a prison art program, revealing art's power for community building and rehabilitation.

ARMR Sciences reports a major breakthrough in the fight against overdose, but can a preventative vaccine truly turn the tide on the fentanyl crisis?

With 33% growth dwarfing industry norms, NNB Nutrition's integrated model and fermentation tech aren't just winning—they're rewriting the rules for wellness.

As a rare Ebola strain rages in a DRC warzone, the G7 pledges massive aid. But with fragile peace deals and no proven cure, is it enough to stop a global crisis?

As R.H. Boyd marks its 130th anniversary, its annual Legacy Ball aims to raise crucial funds, celebrating a history of resilience and investing in future leaders.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

Verge Labs' new AI model promises to predict brain activity from a blood draw, potentially upending the costly and failure-prone world of neurology R&D.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

A new, single-shot vaccine for dogs targets two spreading diseases. This innovation aims to make vet visits less stressful and close critical health gaps.

Amid new Ebola fears, one biotech's rapid C1 platform promises 15-day biologics, eyeing a $25B market beyond just pandemic response. But can it deliver?

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

As leaders gather in Kenya, a new push for a UN treaty reveals the staggering economic and environmental cost of untreated sewage, an overlooked crisis.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

One in six people globally faces infertility, yet a pervasive stigma silences their struggle. A worldwide movement is now uniting millions to demand change.